
We wrote about Xeros only last week at 1.3p. Delve believes the market cap is far too low. Take a read of our note and make your own judgement #XSG
Kelt Smallpox - Low Cap Investor
1K posts

@DawgDaisy
Portfolio reshuffle. Now hold from the lows: #sbds, #acrm, #zed, #snt, #metir, #earn, #ciz, #xsg . Locked into #nfx from much higher entries.

We wrote about Xeros only last week at 1.3p. Delve believes the market cap is far too low. Take a read of our note and make your own judgement #XSG



Last few days ive picked up a few lots of #fin finseta below the placing price of 8.50. Made decent money from this in the csfs days and the set up is better now. Bod heavily invested. Very appealing for a takeover long term from within the sector.

If 'skin in the game', cash in the bank and a couple of products that should reap income many multiples of the mkt cap are your thing, then i advise some weekend due diligence on #xsg Xeros. 1.25 to buy currently.


I see #sbds is getting a good pump today. As per results, tread carefully and bank those profits. Expect an acquisition off the back of any rise, so not all bad news.



Dr Dan Gooding on Nuformix’s NXP002 opportunity in idiopathic pulmonary fibrosis tinyurl.com/24rbumnu #NFX #RNS #Stocks #Nuformix #Pharmaceuticals #Therapeutics #Oncology #Fibrosis #DrugRepurposing #NXP001 #NXP002 #Investing #IdiopathicPulmonaryFibrosis #IPF





#earn earnz plc. Two placing this year to fund acquisitions, one at 125% premium and other 44% premium. Both 7.2p with bod heavily backing each time. SP now low 5s. Similar story playing out as at #yu - which went up over 1,500% from those early days. Foundations being laid.




Proud of @CizzleBio. Their CEO moderated a major panel at #AVBCC2025 on “Advancing Cancer Diagnostics to Commercialization.” Big names from @carisls @AstraZeneca joined the discussion on aligning innovation, access & value in early #cancer detection. #CIZ lnkd.in/gVg9UmAn

Last few months in #ciz has seen rollout of a .co.uk page for patients and clinicians, an LOI with the NHS, private undiluted funding and now further patent protection this time in Canada. LTH's might have lost faith but I think these lows are the time to invest.